Baseline characteristics
| . | KPd cohort (n = 66) . | Dara-KPd (n = 28) . |
|---|---|---|
| Age (y), median (range) | 63 (44-79) | 62 (37-74) |
| >65 y, n (%) | 29 (44) | 11 (39) |
| Sex, n (%) | ||
| Male | 33 (50) | 17 (61) |
| Female | 33 (50) | 11 (39) |
| Race, n (%) | ||
| White | 52 (79) | 9 (32) |
| Black | 11 (17) | 17 (61) |
| Asian | 1 (2) | 1 (4) |
| >1 race | 2 (3) | 1 (4) |
| Unknown | 0 (0) | 0 (0) |
| Ethnicity, n (%) | ||
| Hispanic | 5 (8) | 1 (4) |
| Non-Hispanic | 60 (91) | 27 (96) |
| Unknown | 1 (2) | 0 (0) |
| Eastern Cooperative Oncology Group performance status, n (%) | ||
| 0 | 25 (38) | 18 (64) |
| 1-2 | 41 (62) | 10 (36) |
| International Staging System stage, n (%) | ||
| I | 16 (24) | 14 (50) |
| II | 15 (23) | 4 (14) |
| III | 16 (24) | 5 (18) |
| Unknown | 19 (29) | 5 (18) |
| Fluorescence in situ hybridization cytogenetics, (%) | ||
| Unknown | 9 (14) | 3 (11) |
| Standard risk | 35 (53) | 7 (25) |
| High risk∗ | 22 (33) | 18 (64) |
| t(4;14) | 10 (15) | 2 (7) |
| t(14;16) | 2 (3) | 2 (7) |
| t(14;20) | 0 (0) | 0 (0) |
| del(17p) | 7 (11) | 3 (11) |
| 1q copy number abnormalities | 3 (5) | 8 (29) |
| 1q amplification | 2 (3) | 4 (14) |
| 2+ high-risk abnormalities | 3 (5) | 3 (11) |
| Years since diagnosis, median (range) | 5 (1-18) | 6 (1-11) |
| Prior lines of therapy, median (range) | 2 (1-7) | 1 (1-3) |
| Prior ASCT, n (%) | 56 (85) | 24 (86) |
| Lenalidomide exposed, n (%) | 66 (100) | 28 (100) |
| Lenalidomide-refractory, n (%) | 60 (91) | 23 (82) |
| Bortezomib-exposed, n (%) | 53 (80) | 20 (71) |
| Bortezomib-refractory, n (%) | 15 (23) | 7 (25) |
| Carfilzomib-exposed, n (%) | 11 (17) | 9 (32) |
| Both lenalidomide/bortezomib-refractory, n (%) | 12 (18) | 5 (18) |
| Number of cycles of therapy, median (range), n (%) | 14 (2-59) | 23 (2-51) |
| . | KPd cohort (n = 66) . | Dara-KPd (n = 28) . |
|---|---|---|
| Age (y), median (range) | 63 (44-79) | 62 (37-74) |
| >65 y, n (%) | 29 (44) | 11 (39) |
| Sex, n (%) | ||
| Male | 33 (50) | 17 (61) |
| Female | 33 (50) | 11 (39) |
| Race, n (%) | ||
| White | 52 (79) | 9 (32) |
| Black | 11 (17) | 17 (61) |
| Asian | 1 (2) | 1 (4) |
| >1 race | 2 (3) | 1 (4) |
| Unknown | 0 (0) | 0 (0) |
| Ethnicity, n (%) | ||
| Hispanic | 5 (8) | 1 (4) |
| Non-Hispanic | 60 (91) | 27 (96) |
| Unknown | 1 (2) | 0 (0) |
| Eastern Cooperative Oncology Group performance status, n (%) | ||
| 0 | 25 (38) | 18 (64) |
| 1-2 | 41 (62) | 10 (36) |
| International Staging System stage, n (%) | ||
| I | 16 (24) | 14 (50) |
| II | 15 (23) | 4 (14) |
| III | 16 (24) | 5 (18) |
| Unknown | 19 (29) | 5 (18) |
| Fluorescence in situ hybridization cytogenetics, (%) | ||
| Unknown | 9 (14) | 3 (11) |
| Standard risk | 35 (53) | 7 (25) |
| High risk∗ | 22 (33) | 18 (64) |
| t(4;14) | 10 (15) | 2 (7) |
| t(14;16) | 2 (3) | 2 (7) |
| t(14;20) | 0 (0) | 0 (0) |
| del(17p) | 7 (11) | 3 (11) |
| 1q copy number abnormalities | 3 (5) | 8 (29) |
| 1q amplification | 2 (3) | 4 (14) |
| 2+ high-risk abnormalities | 3 (5) | 3 (11) |
| Years since diagnosis, median (range) | 5 (1-18) | 6 (1-11) |
| Prior lines of therapy, median (range) | 2 (1-7) | 1 (1-3) |
| Prior ASCT, n (%) | 56 (85) | 24 (86) |
| Lenalidomide exposed, n (%) | 66 (100) | 28 (100) |
| Lenalidomide-refractory, n (%) | 60 (91) | 23 (82) |
| Bortezomib-exposed, n (%) | 53 (80) | 20 (71) |
| Bortezomib-refractory, n (%) | 15 (23) | 7 (25) |
| Carfilzomib-exposed, n (%) | 11 (17) | 9 (32) |
| Both lenalidomide/bortezomib-refractory, n (%) | 12 (18) | 5 (18) |
| Number of cycles of therapy, median (range), n (%) | 14 (2-59) | 23 (2-51) |
High-risk cytogenetics refers to any one of the following t(4;14), t(14;16), t(14;20), deletion 17p, and 1q gain or amplification.